Clinical Outcomes for Anaplastic Pancreatic Cancer: A Population-Based Study

Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN.
Journal of the American College of Surgeons (Impact Factor: 5.12). 11/2012; 215(5):627-34. DOI: 10.1016/j.jamcollsurg.2012.06.418
Source: PubMed


Anaplastic pancreatic cancer (APC) is a rare subtype of pancreatic ductal adenocarcinoma (PDA) that can carry a worse overall survival (OS) when compared with other variants. However, the presence of osteoclast-like giant cells (OCGCs) in APC specimens can predict improved OS. The aim of this study was to evaluate the OS of patients with APC (with and without OCGCs) compared with patients with other subtypes of PDA using a population-based registry.
We identified all patients in the Surveillance, Epidemiology and End Results (SEER) database with pathologically confirmed APC and PDA diagnosed between 1988 and 2008. Overall survival was evaluated using Kaplan-Meier and Cox proportional hazard regression.
The study cohort included 5,859 (94.3%) patients with PDA and 353 (5.7%) with APC. Overall survival for all patients with APC was significantly worse than for patients with PDA (hazard ratio [HR] = 1.9; 95% CI, 1.7-2.1; p < 0.001); however, in the subgroup of resected patients, APC (n = 81) had similar OS to PDA (n = 3,517) (HR = 0.9; 95% CI, 0.7-1.2; p = 0.37). Patients with APC tumors with OCGCs (n = 11) demonstrated improved OS when compared with all other APC variants without OCGCs (n = 342) (HR = 0.3; 95% CI, 0.1-0.7; p = 0.004), but this survival difference was not observed in the subgroup of resected patients (HR = 0.5; 95% CI, 0.2-1.4; p = 0.18).
Anaplastic pancreatic cancer is a rare malignancy with poor OS. The diagnosis of APC with OCGCs is predictive of improved OS compared with other patients with APC. This survival benefit, however, is not observed in patients with resected disease.

Download full-text


Available from: Rondell P D Graham
  • Source
    • "In the review by Kobayashi et al. some favorable prognostic factors were identified: younger age at time of diagnosis, female gender, smaller lesions and absence of lymph node involvement[13]. UC-OGCs seem to have a clearly better outcome than tumors with pleomorphic/sarcomatoid giant cells (UC-PGCs) or other variables[11,12]. However, there is still controversy regarding the prognosis of UC- OGCs when compared to ductal adenocarcinoma[6,11,15]. Histogenesis of UC-OGCs is another issue of controversy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Undifferentiated head of pancreas carcinoma with osteoclast-like giant cells (UC-OGC) is a rare neoplasm, with less than a hundred cases reported. We present such a case, in which the UC-OGC presented atypically as a cystic lesion following acute pancreatitis and led to late diagnosis. Presentation of case: A 75-year-old female patient, who had suffered acute pancreatitis three years ago, was referred with a diagnosis of osteoclast-like giant cell (OGC) tumor of the head of pancreas. She had suffered acute pancreatitis three years ago. Two years ago she developed abdominal pain, steatorrhea and weight loss. Abdominal computed tomography imaging showed a cystic mass in the head of the pancreas (maximum diameter 4cm). The initial diagnosis was pancreatic pseudocyst; however as the mass gradually increased in size and the patient continued to be symptomatic, a CT-guided biopsy was performed. Histological examination revealed an OGC pancreatic tumor. In laparotomy a large (9cm) encapsulated heterogeneous mass was found with partial involvement of the common hepatic artery. Pancreaticoduodenectomy was performed and the involved part of the common hepatic artery was replaced with a homologous graft from the major saphenous vein. Post-operative course was uneventful. Histology revealed an undifferentiated pancreatic adenocarcinoma with OGCs. She survived 10 months after the operation. Discussion: Pancreatic undifferentiated carcinomas with OGCs are very rare neoplasms and can present with an atypical clinical picture. Conclusions: A symptomatic cystic lesion of the pancreas, which is growing in size, should be investigated promptly in order to exclude the presence of malignancy.
    Full-text · Article · Dec 2016 · International Journal of Surgery Case Reports
  • Source
    • "The majority of patients were in advanced stages (locally advanced unresectable or metastastic) as they are diagnosed, only 15–20% are surgical candidates. Even with surgery, the 5-year survival following resection is 25–30% for node-negative disease and 10% for nodepositive disease, most of which develop to metastasis/ recurrent disease (Clark et al., 2012; Zaniboni et al., 2012). The 5-year survival rate is <1% with most patients dying within 1 year. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is one of the most lethal human malignancies with a very low 5-year survival rate, which highlights urgent needs for more effective therapeutic strategies. In this study, we examined the potential therapeutic effects of an adenovirus encoding human interferon gamma (Ad-IFNγ) on pancreatic carcinoma cells Capan-2 in vitro and in vivo. The results indicated that Ad-IFNγ could significantly inhibit tumor cell growth via inducing cell apoptosis. After infection, IFNγ expressed durably and stably in xenografts, predominantly in tumor tissue, while much less in blood and liver. Thus, adenovirus-mediated intratumoral injection of human IFNγ gene could be an effective gene therapeutic system for the treatment of pancreatic carcinoma. Anat Rec, 00:000-000, 2013. © 2013 Wiley Periodicals, Inc.
    Preview · Article · Apr 2013 · The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anaplastic pancreatic carcinoma is a rare tumor with poor survival. Data on surgical and medical therapies are currently limited to case reports and case series with small numbers. We describe a case of multifocal anaplastic pancreatic carcinoma treated with neoadjuvant FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) and total pancreatectomy with subsequent patient disease-free survival currently at 12 months. The goal for anaplastic pancreatic carcinoma treatment should continue to be complete surgical resection. Optimum chemotherapeutic options continue to be investigated.
    No preview · Article · May 2013 · JOP: Journal of the pancreas
Show more